Early outcomes after allogeneic hematopoietic SCT in pediatric patients with hematologic malignancies following single fraction TBI

Keyphrases

• Hematological Malignancies 100%
• Pediatric Patients 100%
• Early Outcome 100%
• Single Fraction 100%
• Hematopoietic SCT 100%
• Acute Toxicity 66%
• Lung 33%
• High Risk 33%
• Transplantation 33%
• Overall Survival 33%
• Pediatric 33%
• Renal Failure 33%
• Mucosa 33%
• Disease-free Survival 33%
• Peripheral Blood 33%
• Cataract 33%
• Graft Rejection 33%
• Shock 33%
• Late Complications 33%
• Short Course 33%
• Neurodevelopment 33%
• Transplantation Conditioning 33%
• Multiple Organ Failure 33%
• Endocrine Disorders 33%
• Heavily Pretreated 33%
• Venous Disease 33%
• Methylprednisolone 33%
• Invasive Infection 33%
• Donor Engraftment 33%
• Second Remission 33%
• Hemolytic Anemia 33%
• Mucositis 33%
• Unrelated Donor 33%
• Unrelated Donor Transplantation 33%
• Non-relapse Mortality 33%
• Sterility 33%
• Donor Cells 33%
• Cell Engraftment 33%
• GVHD Prophylaxis 33%

Medicine and Dentistry

• Hematologic Malignancy 100%
• Pediatrics Patient 100%
• Transplantation 66%
• Graft Versus Host Reaction 66%
• Acute Toxicity 66%
• Engraftment 66%
• Infection 33%
• Cataract 33%
• Overall Survival 33%
• Pediatrics 33%
• Mucosa 33%
• Low Drug Dose 33%
• Shock (Circulatory) 33%
• Conditioning 33%
• Disease Free Survival 33%
• Renal Failure 33%
• Graft Rejection 33%
• Methotrexate 33%
• Multiple Organ Dysfunction Syndrome 33%
• Endocrine Disease 33%
• Nerve Cell Differentiation 33%
• Methylprednisolone 33%
• Vein Occlusion 33%
• Hemolytic Anemia 33%
• Mucositis 33%
• Lung 33%
• Non-Relapse Mortality 33%

Immunology and Microbiology

• Graft-Versus-Host Disease 100%
• Engraftment 100%
• Low Drug Dose 50%
• Overall Survival 50%
• Disease Free Survival 50%
• Mucosa 50%
• Methotrexate 50%
• Conditioning 50%
• Methylprednisolone 50%
• Nerve Cell Differentiation 50%